223035 Factors associated with smoking in HIV-infected youth in the LEGACY Cohort

Sunday, November 7, 2010

Karen Pabón-Cruz, MS , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention, Atlanta, GA
Beverly Bohannon, MS RN , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention, Atlanta, GA
John T. Wheeling, MPH , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention and Northrup Grummon, Inc., Atlanta, GA
Kate Buchacz, PhD, MPH , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention, Atlanta, GA
Ken Dominguez, MD MPH , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention, Atlanta, GA
and The LEGACY Consortium , Division of HIV/AIDS Prevention, Epidemiology Branch Clinical Epidemiology Team, Centers for Disease Control and Prevention, Atlanta, GA
Background: A faster decrease in CD4 counts has been associated with smoking in HIV-infected adults. We described the prevalence of, and clinical and psychosocial factors associated with smoking among HIV-infected youth.

Methods: We analyzed data from LEGACY, a CDC-sponsored cohort study (N = 1,085; aged 11-25 years in 2006). We defined “smokers” as participants with medical record documentation of smoking tobacco, marijuana, and/or crack. Univariate and multivariable logistic regressions were performed.

Results: Of 1,085 HIV-infected youth (median age 16 years, 55% female, 65% black and 26% Hispanic), 136 (13%) were smokers: 81% smoked tobacco, 57% smoked marijuana, 3% smoked crack, and 36% smoked more than one substance type. Smokers, compared with nonsmokers, were more likely to be male or older; to have lower median CD4+ counts, higher median viral loads (VL); > 1 AIDS-Defining Condition (ADC); and less likely to be receiving HAART (all p<0.05). After adjusting for age, mode of HIV transmission, and HAART use, factors associated with smoking included having a CD4+ count <200cells/mm3 (adjusted odds ratio [AOR] 3.1; 95% confidence interval [CI] 1.5-5.4), a VL >100,000 copies/ml (AOR 2.3; CI 1.1-5.0), or an ADC (AOR 2.4; CI 1.3-4.4). Being sexually active (AOR 4.3; CI 2.7-6.8), homeless (AOR 5.6; CI 1.6-19.4), or incarcerated (AOR 2.7; CI 1.1-6.7), or having alcohol problems (AOR 14.7; CI 2.7-80.2) were also significantly associated with smoking.

Conclusion: Smoking was associated with poorer immunologic and virologic status. Associated psychosocial factors must be considered in developing anti-smoking interventions in HIV-infected youth.

Learning Areas:
Epidemiology
Public health or related research

Learning Objectives:
1) Describe the prevalence of smoking among HIV-infected youth in the US. 2) Recognize clinical and psychosocial factors that can be related with smoking in this population. 3) Consider associated clinical and psychosocial factors in developing anti-smoking interventions in HIV-infected youth.

Keywords: HIV/AIDS, Adolescents

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present this abstract because it is part of the work that I did as Epidemiology intern at CDC (Centers for Disease Control and Prevention) in Atlanta, during the fall season of 2008. This abstract was cleared by CDC and I received the authorization of my mentor, Dr. Kenneth Dominguez, and the Division of HIV/AIDS Prevention (DHAP) to be the presenting author at APHA. Below I provide Dr. Dominguez' contact information: Kenneth L. Dominguez, MD, MPH; Medical Epidemiologist; CDC, Division of HIV/AIDS Prevention, 1600 Clifton Rd., M/S E-45, Atlanta, GA 30333 Tel. (404)639-6129; Fax. (404)639-6127
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.